Ignite Creation Date:
2024-05-06 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06232122
Status:
RECRUITING
Last Update Posted:
2024-01-30
First Post:
2024-01-20
Brief Title:
Evaluation of 68Ga-FAPI-46 and 18F-FDG PETCT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer
Sponsor:
Chang Gung Memorial Hospital
Organization:
Chang Gung Memorial Hospital
Study Overview
Official Title:
Evaluation of 68Ga-FAPI-46 and 18F-FDG PETCT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer With CA125 Elevation From Complete Response After Therapy
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A prospective cohort imaging study in a single institution to evaluate 68Ga- FAPI-46 and 18F-FDG PETCT imaging for detecting recurrent tumor lesions in patients of ovarian cancer with CA125 elevation from complete response after therapy
Detailed Description:
Ovarian cancer is the eighth most common cancer worldwide in females and usually diagnosed at an advanced stage Serum cancer antigen 125 CA125 is widely used in ovarian cancer An elevation in CA125 levels can precede a clinically apparent recurrence by 3 to 6 months and 18F-FDG PETCT can modify management in approximately half of these patients However 18F-FDG PETCT may yield false negative results 68Ga-FAPI-46 PETCT shows potential here This study is to assess the diagnostic performances of 68Ga-FAPI-46 and 18F-FDG PETCT for ovarian cancer recurrence in patients with CA125 elevation from complete response after therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None